NasdaqGM - Delayed Quote • USD
Clearside Biomedical, Inc. (CLSD)
At close: April 24 at 4:00 PM EDT
After hours: April 24 at 5:08 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 6 | 5 |
| Avg. Estimate | -0.14 | -0.14 | -0.53 | -0.56 |
| Low Estimate | -0.16 | -0.16 | -0.63 | -0.66 |
| High Estimate | -0.12 | -0.12 | -0.46 | -0.44 |
| Year Ago EPS | -0.15 | -0.15 | -0.53 | -0.53 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 6 | 5 |
| Avg. Estimate | 580k | 590k | 2.36M | 7.75M |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | 2.38M | 2.4M | 9.61M | 16.14M |
| Year Ago Sales | 4k | 1.02M | 8.23M | 2.36M |
| Sales Growth (year/est) | 14,400.00% | -42.00% | -71.30% | 228.40% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.14 | -0.14 | -0.15 | -0.09 |
| EPS Actual | -0.15 | -0.15 | -0.15 | -0.08 |
| Difference | -0.01 | -0.01 | 0 | 0.01 |
| Surprise % | -7.10% | -7.10% | 0.00% | 11.10% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.14 | -0.14 | -0.53 | -0.56 |
| 7 Days Ago | -0.14 | -0.14 | -0.53 | -0.56 |
| 30 Days Ago | -0.14 | -0.14 | -0.53 | -0.58 |
| 60 Days Ago | -0.15 | -0.16 | -0.58 | -0.64 |
| 90 Days Ago | -0.15 | -0.16 | -0.58 | -0.64 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | CLSD | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 6.70% | -- | -- | 1.50% |
| Next Qtr. | 6.70% | -- | -- | 11.40% |
| Current Year | 0.00% | -- | -- | 5.20% |
| Next Year | -5.70% | -- | -- | 13.40% |
| Next 5 Years (per annum) | -- | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | Needham: Buy to Buy | 4/11/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/14/2024 |
| Reiterates | JMP Securities: Market Outperform to Market Outperform | 3/13/2024 |
| Maintains | Wedbush: Outperform to Outperform | 3/13/2024 |
| Reiterates | Needham: Buy to Buy | 3/13/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 11/14/2023 |
Related Tickers
ELEV Elevation Oncology, Inc.
3.8800
-10.19%
CRVS Corvus Pharmaceuticals, Inc.
1.5100
-1.31%
LPTX Leap Therapeutics, Inc.
3.2900
+2.81%
CDTX Cidara Therapeutics, Inc.
12.29
+19.90%
GLYC GlycoMimetics, Inc.
1.8550
+1.09%
KPTI Karyopharm Therapeutics Inc.
1.0900
0.00%
CTMX CytomX Therapeutics, Inc.
1.6300
-2.98%
TCON TRACON Pharmaceuticals, Inc.
1.8900
+2.16%
KZR Kezar Life Sciences, Inc.
0.8014
-2.98%
OCUL Ocular Therapeutix, Inc.
4.6450
-7.10%